Starpharma | Sustainability Performance
A pharmaceutical company specializing in dendrimer-based drug delivery technologies.
1997
Australia
11 - 50 employees
Biotechnology
$1M - 10M in revenue
Sustainability Ranking & Industry Benchmark
#8600
Overall#230
in Australia#183
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
- Stantec's environmental consulting involves contaminated site assessment.
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$3.2MFY2025 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
240.0%FY2025
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
-47.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.0
▼ 74.6%
0.0
▲ 218.1%
0.0
▲ 6.3%
0.1
2029Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Available
Recycling policy
Not available
Workplace health & safety policy
Available
56%
Independent Directors
5 out of 9 incl. management
Overall score
58
Environment
39
Social
99
Governance
35
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
